Abstract
Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Current Pharmaceutical Design
Title: Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity
Volume: 7 Issue: 2
Author(s): William A. Banks
Affiliation:
Abstract: Leptin has emerged as a major regulator of adiposity. Leptin is released into the blood from fatcells and circulates to the brain where it crosses the bloodbrain barrier (BBB) to act at receptors within the central nervous system to affect appetite, thermogenesis, and a number of other actions. In humansand in many rodent models, resistance to leptin appears to be a chief cause of obesity. Determining the cause of leptin resistance is fundamental to developing strategies for the use of leptin in obesity. Theliterature characterizing the transport of leptin across the BBB is reviewed. This literature stronglysuggests that the cause of leptin resistance is due a decreased transport of leptin across the BBB in obese humans and rodents. The main cause of this resistance appears to be an impairment in the activity of the transporter rather than just simply saturation at higher doses. Strategies to overcome impaired BBB transport are reviewed, including the use of allosteric regulators and the delivery of material by the intrathecal route.
Export Options
About this article
Cite this article as:
William A. Banks , Leptin Transport Across the Blood-Brain Barrier: Implications for the Cause and Treatment of Obesity, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398310
DOI https://dx.doi.org/10.2174/1381612013398310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Interactions between Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Treatments (Except Anti-Agregant Therapy)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine Opposing Gatekeepers of Apical Sterol Transport: Niemann-Pick C1-Like 1 (NPC1L1) and ATP-Binding Cassette Transporters G5 and G8 (ABCG5/ABCG8)
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology Editorial: Paving the Way for Improved Antiplatelet Therapy
Current Pharmaceutical Design Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Smoking and Weight
Current Respiratory Medicine Reviews Copy Number Variations with Isolated Fetal Ventriculomegaly
Current Molecular Medicine Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets 3D-QSAR analysis of MCD inhibitors by CoMFA and CoMSIA
Combinatorial Chemistry & High Throughput Screening Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design Effects of Hypertension, Diabetes Mellitus, Obesity and Other Factors on Kidney Haemodynamics
Current Vascular Pharmacology Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Sodium-Proton Exchanger Isoform-1: Synthesis of a Potent Inhibitor Labeled with Deuterium and Carbon-14
Current Radiopharmaceuticals Periodontal Bacteria Aggravate Chronic Renal Failure Induced by Subtotal Nephrectomy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)